BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nanoscience Technologies, Inc. Finalizes License Agreement With New York University


10/19/2005 5:08:53 PM

NEW YORK--(BUSINESS WIRE)--Nov. 20, 2003--Nanoscience Technologies, Inc. (OTCBB:NANS - News) announced today that it has finalized a Research and License Agreement (the "License Agreement") with New York University ("NYU"). Under the terms of the License Agreement, NYU granted to Nanoscience a license to certain pre-existing inventions and certain intellectual property to be generated by a designated research project being conducted at NYU relating to DNA Nanotechnology. Structural DNA Nanotechnology seeks to exploit the architectural properties of DNA with the ultimate goal of organizing matter in three dimensions. Pharmaceutical development, nano-electronics and the creation of new materials are among the potential applications of this research.

As compensation to NYU for work to be performed on its research projects, Nanoscience has agreed to provide to NYU minimum funding in the aggregate amount of $1,657,690, in installments commencing on September 15, 2003 through, May 1, 2007, and additional fees and expenses. An initial payment of $300,000 has been paid to NYU. The License Agreement further provides that NYU grants to Nanoscience an exclusive worldwide license to develop, manufacture, use, lease or sell any licensed products and/or processes related to the research project, together with the right to grant sublicenses. Nanoscience in turn will pay to NYU a royalty fee of a varying amount from sales of products and for sublicenses. In connection with and as further consideration for entering into the License Agreement, Nanoscience has issued shares of its common stock to NYU.

Nanoscience also announced that on October 17, 2003, it completed a private placement of 1,222,192 shares of its common stock for $400,000. A portion of the funds were used to make the initial payment to NYU.

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to, the successful results of the NYU research projects, as well as other factors expressed from time to time in Nanoscience's periodic filings with the SEC. As a result, this press release should be read in conjunction with Nanoscience's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Nanoscience undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:

Nanoscience Technologies, Inc., New York Edward F. Cowle, 212-557-4005 edcowle@nanstech.com

Source: Nanoscience Technologies, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES